

ESTIMATED SAVINGS FROM GENERIC DRUG APPROVALS, ACCELERATED BY PBM STRATEGIES TO LOWER COST



(Billions)

Savings based on sales during 12-months following approvals



Source: Estimating Cost Savings from New Generic Drug Approvals in 2018-2020 (fda.gov)